NCT03877952View on ClinicalTrials.gov

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

November 1, 2018

Study Completion Date

November 2, 2018

Conditions
Healthy
Interventions
DRUG

14C-CORT125281

14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY